MaxCyteMXCT -2.36%58 Days Inventory is 441.36 as of Mar. 2026, which is 8% below its 10-year median of 479.63. GuruFocus rates MXCT with a GF Score™ of 58/100 and a GF Value™ of $2.57 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 787 Medical Devices & Instruments companies, MaxCyte ranks worse than 89.33% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). MaxCyte's Average Total Inventories for the
three
months ended in Mar. 2026 was $7.59 Mil. MaxCyte's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $1.57 Mil.
Hence, MaxCyte's Days Inventory for the
three
months ended in Mar. 2026 was 441.36.
The historical rank and industry rank for MaxCyte's Days Inventory or its related term are showing as below:
MXCT'
s Days Inventory Range Over the Past 10 Years
Min: 336.87 Med: 479.63 Max: 800.89
Current: 452.29
During the past 13 years, MaxCyte's highest Days Inventory was 800.89. The lowest was 336.87. And the median was 479.63.
MXCT's Days Inventory is ranked worse than 89.33% of 787
companies
in the Medical Devices & Instruments industry
Industry Median: 179.73
vs MXCT: 452.29
MaxCyte's Days Inventory
declined
from Mar. 2025 (523.85) to Mar. 2026 (441.36).
Inventory Turnover measures how fast the company turns over its inventory within a year.
MaxCyte's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.21.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
MaxCyte's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.79.
MaxCyte (NAS:MXCT) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
MaxCyte's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
MaxCyte's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
MaxCyte Days Inventory Related Terms
MaxCyte Days Inventory Historical Data
* Premium members only.
The historical data trend for MaxCyte's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MXCT vs RCEL, NNOX, SNWV: Days Inventory Comparison
For the Medical Devices subindustry, MaxCyte's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MaxCyte Days Inventory vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, MaxCyte's Days Inventory distribution charts can be found below:
* The bar in red indicates where MaxCyte's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MaxCyte (MXCT) has a Days Inventory of 441.36 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on MaxCyte and its competitors. This is near median its historical median of 479.63. Over the past decade, MaxCyte's Days Inventory has ranged from 336.87 to 800.89. According to the industry distribution chart, MaxCyte ranks #703 out of 787 companies in the Medical Devices & Instruments industry, placing it in the top 89.3%.
Is MaxCyte's Days Inventory too high?
MaxCyte's current Days Inventory of 441.36 is near median its 10-year median of 479.63. Over the past 10 years, this metric has ranged from a low of 336.87 to a high of 800.89. The Medical Devices & Instruments industry median Days Inventory is 179.73. MaxCyte's value of 441.36 is 145.6% above this industry median. Based on the distribution chart, MaxCyte ranks #703 out of 787 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, MaxCyte has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MaxCyte's Days Inventory compare to RCEL and NNOX?
According to the Medical Devices & Instruments industry distribution chart, MaxCyte ranks #703 out of 787 companies for Days Inventory. This places MaxCyte in the lower half of its industry. The industry median Days Inventory is 179.73. MaxCyte's value of 441.36 is 145.6% above this benchmark. Historically, MaxCyte's own Days Inventory has ranged from 336.87 to 800.89 over the past decade. While the company's 10-year median is 479.63 vs. the industry median of 179.73, MaxCyte has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Medical Devices & Instruments company?
The median Days Inventory among Medical Devices & Instruments companies is 179.73, based on 787 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MaxCyte's current Days Inventory of 441.36 is 145.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on MaxCyte and its competitors. For the Medical Devices & Instruments industry, the median Days Inventory is 179.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MaxCyte's current Days Inventory is 441.36, which is near median its own 10-year median of 479.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MaxCyte stock overvalued right now?
Based on GuruFocus' analysis, MaxCyte (MXCT) is currently considered Possible Value Trap. The stock's GF Value™ is $2.57, compared to a current price of $1.25 — trading 51.4% below its estimated fair value. The current Days Inventory is 441.36, which is near median its 10-year median of 479.63 and 145.6% above the Medical Devices & Instruments industry median of 179.73. MaxCyte's overall GF Score™ is 58/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For MaxCyte (MXCT), the current Days Inventory is 441.36 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MaxCyte (MXCT) Overvalued in 2026?
Based on GuruFocus' analysis, MaxCyte stock appears to be undervalued.
The current stock price of $1.25 is trading 51.4% below its estimated GF Value™ of $2.57.
GuruFocus considers MaxCyte to be Possible Value Trap.
Key valuation signals for MXCT:
Days Inventory: 441.36 (near median its 10-year median of 479.63)
GF Value™: $2.57 vs. price of $1.25 (51.4% below fair value)
Industry Position: 145.6% above the Medical Devices & Instruments median (#703 of 787)
No single metric tells the full story. See the MXCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.
58GF Score
Get the complete analysis for MXCT
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MXCT has been successfully added to your 
